Funding for this research was provided by:
Ministero della Salute (RF-2016-02364358, RF-2021-12373889, PNRR-MAD-2022-12375656)
Università degli Studi di Milano
Article History
Received: 11 January 2024
Accepted: 25 February 2024
First Online: 25 April 2024
Declarations
:
: Vittoria Moretti, Stefano Romeo, and Luca Valenti have no conflicts of interest to declare that are relevant to the content of this article.
: This article does not contain any studies with human or animal subjects.
: LV has received speaking fees from MSD, Gilead, AlfaSigma, and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept, Diatech Pharmacogenetics, Ionis Pharmaceuticals, Boehringer Ingelheim, and Resalis Therapeutics, and received unrestricted research grants from Gilead.SR is consultant for Astra Zeneca, RIbocure Ab, Foresite Lab, Novartis, AMGEN, Sanofi, and Ultragenix. SR has received grants from Astra Zeneca for research in steatotic liver disease.